Crossmark Global Holdings Inc. Has $932,000 Stake in Genmab A/S (NASDAQ:GMAB)

Crossmark Global Holdings Inc. reduced its stake in Genmab A/S (NASDAQ:GMAB) by 45.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,245 shares of the company’s stock after selling 32,387 shares during the period. Crossmark Global Holdings Inc.’s holdings in Genmab A/S were worth $932,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Atria Investments Inc lifted its position in shares of Genmab A/S by 42.4% during the 3rd quarter. Atria Investments Inc now owns 48,475 shares of the company’s stock valued at $1,182,000 after acquiring an additional 14,424 shares during the period. Assetmark Inc. lifted its position in Genmab A/S by 16.2% during the third quarter. Assetmark Inc. now owns 82,629 shares of the company’s stock worth $2,014,000 after purchasing an additional 11,519 shares during the period. US Bancorp DE grew its stake in Genmab A/S by 16.0% during the third quarter. US Bancorp DE now owns 171,669 shares of the company’s stock worth $4,185,000 after buying an additional 23,723 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Genmab A/S by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,064 shares of the company’s stock valued at $197,000 after buying an additional 3,137 shares during the period. Finally, Legacy Wealth Asset Management LLC raised its position in shares of Genmab A/S by 1.1% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock valued at $1,097,000 after buying an additional 471 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Redburn Atlantic began coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Price Performance

Genmab A/S stock opened at $21.18 on Friday. The business has a 50 day moving average of $24.08 and a 200-day moving average of $26.28. The company has a market capitalization of $14.02 billion, a P/E ratio of 21.03, a P/E/G ratio of 0.70 and a beta of 0.99. Genmab A/S has a 1 year low of $21.17 and a 1 year high of $32.89.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same quarter last year, the company posted $0.47 earnings per share. Equities analysts anticipate that Genmab A/S will post 1.28 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.